Researchers assessed long-term effectiveness and tolerability of brivaracetam in patients with focal epilepsy. According to this multicenter retrospective study, brivaracetam was effective and well-tolerated in a large population of patients with predominantly drug-resistant epilepsy. There were no unexpected adverse events (AEs) over 1 year. The most frequently reported AEs were somnolence, irritability and dizziness.
September 21, 2020
Texas A&M Neuroscientists Discover New Therapy for Refractory Epilepsy
Using an arithmetic technique to select the best combination two medications with the highest efficacy, researchers state that there is a positive interaction between two neurosteroids brexanolone and ganaxolone and two antiepileptic medications tiagabine and midazolam.
September 16, 2020
Body Cooling May Shorten Refractory Seizures in Dravet and Other Epilepsies
Used in addition to standard treatments, therapeutic hypothermia – based on lowering the body’s temperature – can shorten the duration of long-lasting seizures in drug-resistant forms of epilepsy, a study finds.